The global anticoagulants market size is calculated at USD 37.08 billion in 2025 and is forecasted to reach around USD 81.16 billion by 2034, accelerating at a CAGR of 9.11% from 2025 to 2034. The North America market size surpassed USD 20.02 billion in 2024 and is expanding at a CAGR of 9.15% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Anticoagulants Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Anticoagulants Market, by Indication of disease
8.1.1. Pulmonary Embolism (PE)
8.1.1.1. Market Revenue and Forecast
8.1.2. Deep Vein Thrombosis (DVT)
8.1.2.1. Market Revenue and Forecast
8.1.3. Atrial Fibrillation
8.1.3.1. Market Revenue and Forecast
8.1.4. Heart Attacks
8.1.4.1. Market Revenue and Forecast
8.1.5. Others
8.1.5.1. Market Revenue and Forecast
9.1. Anticoagulants Market, by Administration Route
9.1.1. Oral
9.1.1.1. Market Revenue and Forecast
9.1.2. Injectable
9.1.2.1. Market Revenue and Forecast
10.1. Anticoagulants Market, by Drug Class
10.1.1. NOACs
10.1.1.1. Market Revenue and Forecast
10.1.2. Heparin & LMWH
10.1.2.1. Market Revenue and Forecast
10.1.3. Vitamin K Antagonist
10.1.3.1. Market Revenue and Forecast
10.1.4. Others
10.1.4.1. Market Revenue and Forecast
11.1. Anticoagulants Market, by Distribution Channel
11.1.1. Hospitals Pharmacies
11.1.1.1. Market Revenue and Forecast
11.1.2. Retail Pharmacies
11.1.2.1. Market Revenue and Forecast
11.1.3. Online Pharmacy
11.1.3.1. Market Revenue and Forecast
11.1.4. Others
11.1.4.1. Market Revenue and Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Indication of disease
12.1.2. Market Revenue and Forecast, by Administration Route
12.1.3. Market Revenue and Forecast, by Drug Class
12.1.4. Market Revenue and Forecast, by Distribution Channel
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Indication of disease
12.1.5.2. Market Revenue and Forecast, by Administration Route
12.1.5.3. Market Revenue and Forecast, by Drug Class
12.1.5.4. Market Revenue and Forecast, by Distribution Channel
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Indication of disease
12.1.6.2. Market Revenue and Forecast, by Administration Route
12.1.6.3. Market Revenue and Forecast, by Drug Class
12.1.6.4. Market Revenue and Forecast, by Distribution Channel
12.2. Europe
12.2.1. Market Revenue and Forecast, by Indication of disease
12.2.2. Market Revenue and Forecast, by Administration Route
12.2.3. Market Revenue and Forecast, by Drug Class
12.2.4. Market Revenue and Forecast, by Distribution Channel
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Indication of disease
12.2.5.2. Market Revenue and Forecast, by Administration Route
12.2.5.3. Market Revenue and Forecast, by Drug Class
12.2.5.4. Market Revenue and Forecast, by Distribution Channel
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Indication of disease
12.2.6.2. Market Revenue and Forecast, by Administration Route
12.2.6.3. Market Revenue and Forecast, by Drug Class
12.2.6.4. Market Revenue and Forecast, by Distribution Channel
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Indication of disease
12.2.7.2. Market Revenue and Forecast, by Administration Route
12.2.7.3. Market Revenue and Forecast, by Drug Class
12.2.7.4. Market Revenue and Forecast, by Distribution Channel
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Indication of disease
12.2.8.2. Market Revenue and Forecast, by Administration Route
12.2.8.3. Market Revenue and Forecast, by Drug Class
12.2.8.4. Market Revenue and Forecast, by Distribution Channel
12.3. APAC
12.3.1. Market Revenue and Forecast, by Indication of disease
12.3.2. Market Revenue and Forecast, by Administration Route
12.3.3. Market Revenue and Forecast, by Drug Class
12.3.4. Market Revenue and Forecast, by Distribution Channel
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Indication of disease
12.3.5.2. Market Revenue and Forecast, by Administration Route
12.3.5.3. Market Revenue and Forecast, by Drug Class
12.3.5.4. Market Revenue and Forecast, by Distribution Channel
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Indication of disease
12.3.6.2. Market Revenue and Forecast, by Administration Route
12.3.6.3. Market Revenue and Forecast, by Drug Class
12.3.6.4. Market Revenue and Forecast, by Distribution Channel
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Indication of disease
12.3.7.2. Market Revenue and Forecast, by Administration Route
12.3.7.3. Market Revenue and Forecast, by Drug Class
12.3.7.4. Market Revenue and Forecast, by Distribution Channel
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Indication of disease
12.3.8.2. Market Revenue and Forecast, by Administration Route
12.3.8.3. Market Revenue and Forecast, by Drug Class
12.3.8.4. Market Revenue and Forecast, by Distribution Channel
12.4. MEA
12.4.1. Market Revenue and Forecast, by Indication of disease
12.4.2. Market Revenue and Forecast, by Administration Route
12.4.3. Market Revenue and Forecast, by Drug Class
12.4.4. Market Revenue and Forecast, by Distribution Channel
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Indication of disease
12.4.5.2. Market Revenue and Forecast, by Administration Route
12.4.5.3. Market Revenue and Forecast, by Drug Class
12.4.5.4. Market Revenue and Forecast, by Distribution Channel
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Indication of disease
12.4.6.2. Market Revenue and Forecast, by Administration Route
12.4.6.3. Market Revenue and Forecast, by Drug Class
12.4.6.4. Market Revenue and Forecast, by Distribution Channel
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Indication of disease
12.4.7.2. Market Revenue and Forecast, by Administration Route
12.4.7.3. Market Revenue and Forecast, by Drug Class
12.4.7.4. Market Revenue and Forecast, by Distribution Channel
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Indication of disease
12.4.8.2. Market Revenue and Forecast, by Administration Route
12.4.8.3. Market Revenue and Forecast, by Drug Class
12.4.8.4. Market Revenue and Forecast, by Distribution Channel
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Indication of disease
12.5.2. Market Revenue and Forecast, by Administration Route
12.5.3. Market Revenue and Forecast, by Drug Class
12.5.4. Market Revenue and Forecast, by Distribution Channel
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Indication of disease
12.5.5.2. Market Revenue and Forecast, by Administration Route
12.5.5.3. Market Revenue and Forecast, by Drug Class
12.5.5.4. Market Revenue and Forecast, by Distribution Channel
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Indication of disease
12.5.6.2. Market Revenue and Forecast, by Administration Route
12.5.6.3. Market Revenue and Forecast, by Drug Class
12.5.6.4. Market Revenue and Forecast, by Distribution Channel
13.1. Johnson & Johnson
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Bristol-Myers Squibb Company
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Daiichi Sankyo Company
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Bayer AG
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. BoehringerIngelheim GmbH
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Aspen Holdings
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. GlaxoSmithKline Plc
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Pfizer Inc.
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Sanofi S.A.
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Portola Pharmaceuticals
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample